Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report

被引：0
|
作者：
Zhuang, Hongkai [1 ,2 ]
Ma, Zuyi [1 ,2 ]
Wu, Yanxia [3 ]
Yin, Zi [1 ]
Jian, Zhixiang [1 ]
Zhang, Chuanzhao [1 ]
Hou, Baohua [1 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gen Surg, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Shantou Univ, Med Coll, Shantou 515000, Peoples R China
[3] Sun Yat Sen Univ, Sch Med, Guangzhou 510080, Peoples R China
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Castleman disease; neo-adjuvant chemotherapy; plasma cell type; case report;
D O I：
10.21037/tcr.2020.02.45
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future.
引用
收藏
页码：3030 / 3033
页数：4
相关论文
共 50 条
  • [31] Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial
    Ayez, Ninos
    van der Stok, Eric P.
    de Wilt, Hans
    Radema, Sandra A.
    van Hillegersberg, Richard
    Roumen, Rudi M.
    Vreugdenhil, Gerard
    Tanis, Pieter J.
    Punt, Cornelis J.
    Dejong, Cornelis H.
    Jansen, Rob L.
    Verheul, Henk M.
    de Jong, Koert P.
    Hospers, Geke A.
    Klaase, Joost M.
    Legdeur, Marie-Cecile
    van Meerten, Esther
    Eskens, Ferry A.
    van der Meer, Nelly
    van der Holt, Bruno
    Verhoef, Cornelis
    Grunhagen, Dirk J.
    BMC CANCER, 2015, 15
  • [32] Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study
    Ferrandina, Gabriella
    Corrado, Giacomo
    Vitrano, Giuseppe
    Gallotta, Valerio
    Palluzzi, Eleonora
    Distefano, Mariagrazia
    Scambia, Giovanni
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 431 - 438
  • [33] Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study
    Ferrandina, Gabriella
    Palluzzi, Eleonora
    Gallotta, Valerio
    Gambacorta, Maria Antonietta
    Autorino, Rosa
    Turco, Luigi Carlo
    Macchia, Gabriella
    Cosentino, Francesco
    Gui, Benedetta
    Mattoli, Maria Vittoria
    Ronzino, Graziana
    Valentini, Vincenzo
    Scambia, Giovanni
    EJSO, 2018, 44 (07): : 1062 - 1068
  • [34] Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study
    Gabriella Ferrandina
    Giacomo Corrado
    Giuseppe Vitrano
    Valerio Gallotta
    Eleonora Palluzzi
    Mariagrazia Distefano
    Giovanni Scambia
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 431 - 438
  • [35] Does response in primary breast cancer correlate with the axillary response after Neo-adjuvant chemotherapy in node-positive disease?
    Agrawal, A.
    Soliman, M.
    Sivakanthan, T.
    Ahmed, B.
    Provenzano, E.
    BREAST, 2025, 80
  • [36] Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: The CHARISMA randomized multicenter clinical trial.
    van der Stok, Eric P.
    Verhoef, Cornelis
    Grunhagen, Dirk J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Letter to the editor "Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice"
    Saveetha, Silambarasan Tamil Selvan
    ORAL ONCOLOGY, 2024, 156
  • [38] Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer A case report
    Jung, Sung Ui
    Jung, Minjung
    Choi, Jin Hyuk
    Jeon, Chang Wan
    MEDICINE, 2021, 100 (14) : E25175
  • [39] Prognostic Significance of Histological Tumor Regression at Primary Site and Nodal Metastases in Patients with Oral Squamous Cell Carcinoma, Treated by Neo-Adjuvant Chemotherapy Followed by Surgery
    Ashwini, N.
    Prabhash, Kumar
    Kane, Shubhada
    D'Cruz, Anil
    Bal, Munita
    Kaushal, Rajiv
    Patil, Asawari
    LABORATORY INVESTIGATION, 2016, 96 : 326A - 326A
  • [40] Prognostic Significance of Histological Tumor Regression at Primary Site and Nodal Metastases in Patients with Oral Squamous Cell Carcinoma,Treated by Neo-Adjuvant Chemotherapy Followed by Surgery
    Prabhash, Ashwini N. Kumar
    Kane, Shubhada
    D'Cruz, Anil
    Bal, Munila
    Kaushal, Rajiv
    Patil, Asawari
    MODERN PATHOLOGY, 2016, 29 : 326A - 326A
12345